Introduction：Basic information about CAS 189060-13-7|Lapaquistat Acetate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lapaquistat Acetate |
|---|
| CAS Number | 189060-13-7 | Molecular Weight | 645.14000 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C33H41ClN2O9 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 2-[1-[2-[(3R,5S)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid |
|---|
| Synonym | More Synonyms |
|---|
Lapaquistat Acetate BiologicalActivity
| Description | Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene[1]. Lapaquistat acetate (TAK-475) is originally intended use to Mevalonate Kinase Deficiency (MKD), it is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage[2]. |
|---|
| Related Catalog | Research Areas >>Metabolic DiseaseSignaling Pathways >>Metabolic Enzyme/Protease >>Farnesyl Transferase |
|---|
| Target | Squalene synthase[1] |
|---|
| References | [1]. Stein EA, et al. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. [2]. Marcuzzi A, et al. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice. Curr Med Chem. 2018;25(24):2783-2796. |
|---|
Chemical & Physical Properties
| Molecular Formula | C33H41ClN2O9 |
|---|
| Molecular Weight | 645.14000 |
|---|
| Exact Mass | 644.25000 |
|---|
| PSA | 131.91000 |
|---|
| LogP | 4.87400 |
|---|
| InChIKey | CMLUGNQVANVZHY-POURPWNDSA-N |
|---|
| SMILES | COc1cccc(C2OC(CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)c3ccc(Cl)cc32)c1OC |
|---|
Synonyms
| Lapaquistat acetate |
| UNII-IUH3AY74O3 |
| TAK-475 |
